Detalhe da pesquisa
1.
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
N Engl J Med
; 386(23): 2188-2200, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443106
2.
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
J Infect Dis
; 228(8): 1055-1059, 2023 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37280116
3.
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Clin Infect Dis
; 76(7): 1247-1256, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411267
4.
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
N Engl J Med
; 380(3): 229-241, 2019 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30650326
5.
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
N Engl J Med
; 380(3): 215-228, 2019 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30650322
6.
Living with tuberculosis: a qualitative study of patients' experiences with disease and treatment.
BMC Public Health
; 22(1): 1717, 2022 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36085073
7.
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria.
Pharmacogenet Genomics
; 30(7): 161-165, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32433338
8.
Thrombocytopenia Impairs Host Defense Against Burkholderia pseudomallei (Melioidosis).
J Infect Dis
; 219(4): 648-659, 2019 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30312422
9.
Role of Toll-Like Receptor 5 (TLR5) in Experimental Melioidosis.
Infect Immun
; 87(8)2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31109950
10.
Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data.
Bull World Health Organ
; 97(12): 828-836, 2019 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31819291
11.
Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.
Antimicrob Agents Chemother
; 62(11)2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30201820
12.
A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers.
Br J Clin Pharmacol
; 84(3): 482-489, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29168205
13.
Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials.
Clin Infect Dis
; 65(1): 46-54, 2017 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28402396
14.
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
N Engl J Med
; 380(19): 1876, 2019 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31067385
15.
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
J Infect Dis
; 213(5): 794-9, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26500351
16.
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
Antimicrob Agents Chemother
; 60(12): 7321-7332, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27697758
17.
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
Malar J
; 15: 97, 2016 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26888075
18.
Time-to-detection in culture predicts risk of Mycobacterium tuberculosis transmission: a cohort study.
Clin Infect Dis
; 59(2): 177-85, 2014 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24729491
19.
Limited role for ASC and NLRP3 during in vivo Salmonella Typhimurium infection.
BMC Immunol
; 15: 30, 2014 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25115174
20.
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Nat Med
; 30(3): 896-904, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38365949